Key players in Enzyme Replacement Therapy
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 |  Sanofi |
sanofi.com (opens in a new tab) | 1,386 reports |
| 2 |  Takeda Pharmaceutical Company Ltd |
takeda.com (opens in a new tab) | 660 reports |
| 3 | BioMarin | — | 165 reports |
| 4 | Amicus Therapeutics | — | 66 reports |
| 5 | Chiesi | — | 99 reports |
Also active in Enzyme Replacement Therapy
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
| Company | Where public records show them |
|---|---|
| Navinta LLC | |
| Actelion | |
| ANI Pharmaceuticals | |
| Edenbridge Pharmaceuticals | |
| Shire Human Genetic | |
| Denali Therapeutics Inc. |
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Enzyme Replacement Therapy reports by place
Australia
Brazil
Canada
China
Ecuador
Egypt
France
Germany
Hong Kong
India
Italy
Japan
Kenya
Malaysia
Mexico
New Zealand
PhilippinesGet the full Enzyme Replacement Therapy report
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.